SMMT — SUMMIT THERAPEUTICS PLC (Healthcare >> Biotechnology)
SMMT FAQ
What is SMMT's ROE?
SUMMIT THERAPEUTICS PLC reports a Return on Equity (ROE) of -210.67%.
What is SMMT's dividend yield?
SUMMIT THERAPEUTICS PLC offers a dividend yield of 0.00%.
What is SMMT's Deepscope Quality Score?
Deepscope rates SMMT's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SMMT?
Deepscope's AI Timing Score for SMMT is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SMMT belong to?
SUMMIT THERAPEUTICS PLC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 13.08
Price
0.03
(0.23%)
Day Change
|
|
|---|
SMMT Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 31) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
Tăng trưởng ROE là âm trong năm ngoái.
ROA quá thấp so với ROE
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt , ...
| Yếu tố Chất lượng |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 79 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 13.08 |
| PBV / Sector |
25.44 / 4.79
|
| Earning Per Share | -1.08 |
| PE / Sector |
N/A / 18.05
|
| PEG or PE/Growth / Sector |
N/A / 0.62
|
| Average 1M Daily Value |
91.41 M
|
| Average 1W Daily Value |
95.17 M
|
| Yếu tố Kỹ thuật |
|
28% |
| Sức khỏe tài chính |
|
47% |
| Khả năng kiếm lợi nhuận |
|
47% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-12 09:43:20 |
| Symbol | SMMT |
| Name | SUMMIT THERAPEUTICS PLC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 776.16 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 10,532.53 / 9,010.81 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 601 Brickell Key Drive, Miami, FL, United States, 33131
Phone: 305 203 2034
Website: https://www.smmttx.com
Employees: 265
Sector: Healthcare >> Biotechnology
Description: Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google